MaxCyte Q1 revenue $8.6M (-26% YoY), net loss $10.9M; cuts FY23 revenue growth guidance to 8-12%

MAXCYTE, INC.

2023-Q1 EPS reported -$0.11 revenue$8,576,300

Total revenue $8.6M, down 26% YoY; core business revenue $7.8M, down 19%.
Net loss $10.9M vs $4.1M; EBITDA loss $12.2M vs $3.7M.
FY23 total revenue growth guidance lowered to 8%-12%; core revenue growth 5%-10%.
Two new SPL partnerships signed: Walking Fish Therapeutics (May) and Catamaran Bio (Jan).
Douglas J. Swirsky appointed CFO, effective immediately.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MAXCYTE, INC. reported First quarter ended March 31, 2023 results: net income Net loss of $10.9 million.

Period: First quarter ended March 31, 2023
Net income: Net loss of $10.9 million
Result: reported results

Exact text from the filing

Total revenue for the first quarter of 2023 was $8.6 million, compared to $11.6 million in the first quarter of 2022, representing a decline of 26%.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MAXCYTE, INC. reported First quarter ended March 31, 2023 results: net income Net loss of $10.9 million.

Period: First quarter ended March 31, 2023
Net income: Net loss of $10.9 million
Result: reported results

Exact text from the filing

First quarter 2023 net loss was $10.9 million compared to net loss of $4.1 million for the same period in 2022.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

MAXCYTE, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-009107

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.